Rosenberg S A
Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20892, USA.
J Natl Cancer Inst. 1996 Nov 20;88(22):1635-44. doi: 10.1093/jnci/88.22.1635.
Tumor-infiltrating lymphocytes (TILs) have been grown from patients with metastatic melanoma and administered to the autologous patients to identify those TIL populations capable of mediating tumor regression. These TILs have been used to clone the genes that encode melanoma antigens. With the use of this strategy, we have identified six different genes encoding antigens restricted by multiple HLA alleles that appear to be related to tumor regression in patients. These antigens are now being used to develop immunization approaches for the treatment of patients with metastatic melanoma. The availability of genes encoding unique cancer antigens is opening new possibilities for the development of immunotherapies for the treatment of patients with cancer.
肿瘤浸润淋巴细胞（TILs）已从转移性黑色素瘤患者体内培养出来，并给予自体患者，以鉴定那些能够介导肿瘤消退的TIL群体。这些TILs已被用于克隆编码黑色素瘤抗原的基因。通过使用这种策略，我们已经鉴定出六个不同的基因，它们编码受多种HLA等位基因限制的抗原，这些抗原似乎与患者的肿瘤消退有关。目前，这些抗原正被用于开发治疗转移性黑色素瘤患者的免疫疗法。编码独特癌症抗原的基因的可用性为开发治疗癌症患者的免疫疗法开辟了新的可能性。
